Teclison Ltd.
Nivolumab Injectable Product
Hepatocellular Carcinoma
Countdown
176days
Phase 2 readout · Dec 30, 2026
What's at stake
Phase 2 trial results for Nivolumab Injectable Product in Hepatocellular Carcinoma are due Dec 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT03259867: Phase 2 trial, sponsor Teclison Ltd., drug Nivolumab Injectable Product. Primary completion date 2026-12-30 (estimated).”